Slc22a1, also known as the gene encoding the organic cation transporter 1 (hOCT1), is a significant member of the SLC22 transporter family. hOCT1 is expressed in most epithelial barriers and different drug target cells, contributing to drug pharmacokinetics and pharmacodynamics. It mediates the translocation of various drugs and is involved in multiple biological processes [2].

In chronic myeloid leukemia (CML), carriers of SLC22A1 rs628031A allele or rs683369G allele were associated with a lower major molecular response (MMR) rate when treated with imatinib [1]. In the context of drug disposition, SLC22A1 polymorphisms have an impact on metformin clinical parameters, such as affecting the area under the concentration-time curve, Cmax, and responsiveness [2]. In Mexican women, genetic variants in SLC22A1 were related to serum lipid levels, with certain genotypes and haplotypes associated with elevated cholesterol, LDL-c, and HDL-c levels [3]. In children with acute lymphoblastic leukemia in the Amazon region, the SLC22A1 gene variant was associated with a higher risk of severe infectious toxicity during treatment [4].

In conclusion, Slc22a1 plays a crucial role in drug transport and disposition, influencing the efficacy and toxicity of drugs in various disease conditions like CML, diabetes, and leukemia. Its genetic variants also have an impact on lipid metabolism. The study of Slc22a1 helps in understanding the role of drug transporters in disease treatment and the influence of genetic factors on drug response.